MYNZ_OUT_1 [2025-04-02 14:37:53 -0400] 2790 Bytes | 794 tokens | Cum: 794 tkns (9.93% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Mainz Biomed N.V. (MYNZ) which is at 3.43 up from 2.93. So, I pulled together a bunch of data for you to look over real fast. It's still early, 2:37:52 PM on Wed Apr 02, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Mainz Biomed N.V. (MYNZ)
IPO: 2021-11-05 (3 Years Ago)
Market Cap: $6,509,279
Shares Outstanding: 2,220,000
Exchange: XNAS
Description: Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Here's the first list of news for Mainz Biomed N.V.:

C1 - Apr-01-25 08:01AM - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
C2 - Mar-28-25 06:49AM - Mainz enrols first subject in study to evaluate colorectal cancer test
C3 - Mar-27-25 09:01AM - Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
C4 - Mar-20-25 10:35AM - Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
C5 - Mar-19-25 05:35PM - Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
C6 - Mar-13-25 08:01AM - Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
C7 - Mar-03-25 08:01AM - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
C8 - Feb-20-25 08:01AM - Mainz Biomed Expands into Switzerland with labor team w

Prior AI Reports for MYNZ:
1. 2025-03-20 – Score: 1 – Target: 5.1450 – Highs: 5.3400 / 4.8250 / 4.80
mainz-biomed-showing-signs-of-recovery-despite-bearish-trend

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Mainz Biomed N.V. (MYNZ)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

MYNZ_OUT_3 [2025-04-02 14:37:57 -0400] 1107 Bytes | 319 tokens | Cum: 1115 tkns (13.94% of 8k)
==========================================================================

Showing C1 (chunk 1 of 6): C1:
**Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update**
Date: Apr-01-25 08:01AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/01/3053314/0/en/Mainz-Biomed-Reports-2024-Financial-Results-and-Provides-Corporate-Update.html

April 01, 2025 08:01 ET| Source:Mainz BioMed NVMainz BioMed NV

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert®in Europe

Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus

Strategic partnerships with industry leaders mark key progress

Company highlights its early accomplishments for 2025

BERKELEY, Calif. and MAINZ, Germany, April 01, 2025 (GLOBE NEWSWIRE) --Mainz Biomed N.V.(NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detectio

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MYNZ_OUT_5 [2025-04-02 14:37:58 -0400] 968 Bytes | 277 tokens | Cum: 1481 tkns (18.51% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T12:23:43Z - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update...
A2 - 2025-04-01T12:01:00Z - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update...
A3 - 2025-04-01T12:25:08Z - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update | Taiwan News | Apr. 1, 20...
A4 - 2025-04-01T12:01:00Z - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - Mainz Biomed (NASDAQ:MYN...
A5 - 2025-04-01T12:01:07Z - EQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MYNZ_OUT_7 [2025-04-02 14:38:01 -0400] 1100 Bytes | 302 tokens | Cum: 1785 tkns (22.31% of 8k)
==========================================================================

Showing A1 (chunk 1 of 14): A1:
**Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update**Date: 2025-04-01Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/01/tmt-newswire/globenewswire/mainz-biomed-reports-2024-financial-results-and-provides-corporate-update/2084308Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe

Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus

Strategic partnerships with industry leaders mark key progress

Company highlights its early accomplishments for 2025

BERKELEY, Calif. and MAINZ, Germany, April 01, 2025 (GLOBE N

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MYNZ_OUT_9 [2025-04-02 14:38:02 -0400] 1047 Bytes | 303 tokens | Cum: 2169 tkns (27.11% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-01T12:01:00Z - Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
B2 - 2025-03-03T13:01:00Z - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
B3 - 2025-02-20T13:01:00Z - Mainz Biomed Expands into Switzerland with labor team w
B4 - 2025-01-21T13:01:00Z - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
B5 - 2024-12-19T13:01:00Z - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
B6 - 2024-12-13T01:00:00Z - Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MYNZ_OUT_11 [2025-04-02 14:38:06 -0400] 721 Bytes | 202 tokens | Cum: 2373 tkns (29.66% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/01/3053314/0/en/Mainz-Biomed-Reports-2024-Financial-Results-and-Provides-Corporate-Update.htmlMainz Biomed reported a 33% increase in lab network revenue, a 30% decrease in operating loss, and an 18% decrease in net loss in 2024. The company made progress with strategic partnerships and its next-generation colorectal cancer screening product.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

MYNZ_OUT_13 [2025-04-02 14:38:07 -0400] 238 Bytes | 59 tokens | Cum: 2522 tkns (31.52% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MYNZ_OUT_15 [2025-04-02 14:38:18 -0400] 3265 Bytes | 826 tokens | Cum: 3351 tkns (41.89% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 83,833 | Perf Month: -30.30% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 219.63K | Perf Quarter: -24.34% | Short Float: 6.09% | ROE: - |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.50 | Index: - | Short Ratio: 0.59 | ROI: - |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 37.60 | Market Cap: 7.67M | Short Interest: 0.13M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.64 | Shs Outstand: 2.22M | Beta: 0.53 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -20.99% | Shs Float: 2.11M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -34.68% | Inst Own: 11.04% | Sales past 5Y: - | Earnings: Apr 01 BMO |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -64.88% | Insider Own: 4.98% | Employees: 26 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: -19.20% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.525
Average Volume: 173396.0
30-Day High: 5.61
30-Day Low: 2.93
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

MYNZ_OUT_17 [2025-04-02 14:38:20 -0400] 676 Bytes | 167 tokens | Cum: 3743 tkns (46.79% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

MYNZ_IN_19 [2025-04-02 14:38:20 -0400] 126 Bytes | 29 tokens | Cum: 3800 tkns (47.50% of 8k)
==========================================================================

====================================
[2025-04-02 14:38:20] # Analysis Completed
Elapsed Time: 27.82 seconds